Neutralizing antibody P2-1D5 neutralizing sars-cov-2 and its application
By screening and preparing P2-1D5 antibodies, the problem of decreased neutralizing activity of existing vaccines and monoclonal antibodies against novel coronavirus mutant strains was solved, achieving potent neutralization against multiple mutant strains and providing a broad-spectrum prevention and control measure.
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- TSINGHUA UNIVERSITY
- Filing Date
- 2023-02-01
- Publication Date
- 2026-08-04
AI Technical Summary
Existing vaccines and monoclonal antibodies have reduced neutralizing activity against novel coronavirus mutant strains, highlighting the urgent need to develop broad-spectrum neutralizing antibodies against SARS-CoV-2 to combat infection from multiple mutant strains.
P2-1D5 antibodies were screened and prepared. Memory B cells were screened from peripheral blood mononuclear cells of infected individuals to obtain monoclonal antibodies that specifically bind to the SARS-CoV-2 spike protein and have broad-spectrum neutralizing ability.
The P2-1D5 antibody exhibits strong neutralizing ability against wild-type novel coronavirus and various natural variants, providing an effective means of prevention and control.
Smart Images
Figure SMS_1 
Figure HDA0004057531620000011
Abstract
Description
Technical Field
[0001] This invention belongs to the field of biotechnology and relates to a broad-spectrum neutralizing antibody P2-1D5 that neutralizes SARS-CoV-2 and its applications. Background Technology
[0002] COVID-19 infection is caused by a novel coronavirus. The main symptoms are low-grade fever, fatigue, and dry cough. A few patients may also experience upper respiratory and digestive symptoms such as nasal congestion, runny nose, and diarrhea. Severe cases can develop acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation disorders, and multiple organ failure. The novel coronavirus (SARS-CoV-2) belongs to the β-coronavirus genus.
[0003] During its transmission, SARS-CoV-2 has undergone numerous mutations, enhancing its transmissibility and immune evasion. Currently, the main circulating naturally occurring mutant strains include the Alpha strain discovered in the UK, the Beta strain in South Africa, and the Gamma strain in Brazil. Vaccination against the novel coronavirus has also been affected. The neutralizing activity of inactivated vaccine serum against the South African mutant strain has decreased by half, and the neutralizing activity of mRNA vaccine serum against the South African mutant strain has decreased by approximately tenfold. Many monoclonal antibodies have also shown weakened or lost neutralizing activity against the mutant strain.
[0004] Monoclonal antibodies can be mass-produced industrially. Their high affinity and specificity for antigen binding significantly reduce adverse reactions in clinical applications. Furthermore, antibody molecules can be modified to increase their antiviral efficacy. Antibodies, with their specificity and flexibility of use, are a very promising tool in the treatment of infectious diseases. Currently, there is an urgent need to address the challenges posed by naturally occurring mutant strains of the novel coronavirus. Developing broad-spectrum human monoclonal antibodies against the novel coronavirus will provide more effective prevention and treatment for infections caused by these naturally occurring mutant strains. Summary of the Invention
[0005] The purpose of this invention is to provide a broad-spectrum neutralizing antibody P2-1D5 that neutralizes SARS-CoV-2 and its applications.
[0006] This invention provides an IgG antibody, named P2-1D5 antibody, composed of a light chain and a heavy chain; the CDR1, CDR2, and CDR3 in the variable region of the heavy chain are shown as positions 26-33, 51-58, and 97-109 in SEQ ID NO: 1, respectively; the CDR1, CDR2, and CDR3 in the variable region of the light chain are shown as positions 27-32, 50-52, and 89-96 in SEQ ID NO: 4, respectively.
[0007] Specifically, the heavy chain variable region is shown in SEQ ID NO: 1.
[0008] Specifically, the light chain variable region is shown in SEQ ID NO: 4.
[0009] Specifically, the heavy chain is either (a) or (b) as follows: (a) the protein represented by positions 20-469 of SEQ ID NO: 2; (b) the protein represented by SEQ ID NO: 2.
[0010] Specifically, the light chain is either (c) or (d) as follows: (c) the protein shown at positions 20-232 of SEQ ID NO: 5; (d) the protein shown in SEQ ID NO: 5.
[0011] The gene encoding the IgG antibody is also within the scope of protection of this invention.
[0012] Specifically, the gene encoding the heavy chain is as follows (1) or (2): (1) The DNA molecule represented by nucleotides 949-2301 in SEQ ID NO: 3; (2) The DNA molecule represented by nucleotides 892-2301 in SEQ ID NO:3.
[0013] Specifically, the gene encoding the light chain is as follows (3) or (4): (3) The DNA molecule represented by nucleotides 1095-1736 in SEQ ID NO: 6; (4) The DNA molecule represented by nucleotides 1038-1736 in SEQ ID NO: 6.
[0014] This invention also protects the use of any of the above-described IgG antibodies in the preparation of medicaments for inhibiting the novel coronavirus.
[0015] The present invention also protects a drug for inhibiting the novel coronavirus, the active ingredient of which is any of the IgG antibodies described above.
[0016] This invention also protects the use of any of the above-described IgG antibodies in the preparation of medicaments for neutralizing the novel coronavirus.
[0017] The present invention also protects a drug for neutralizing the novel coronavirus, the active ingredient of which is any of the IgG antibodies described above.
[0018] The present invention also protects the use of any of the above-described IgG antibodies in the preparation of medicaments for the prevention and / or treatment of COVID-19 infection.
[0019] The present invention also protects a medicament for the prevention and / or treatment of COVID-19 infection, wherein the active ingredient is any of the IgG antibodies described above.
[0020] The COVID-19 infection mentioned above refers to infection with the novel coronavirus.
[0021] The novel coronavirus mentioned above is either a wild-type novel coronavirus or a naturally occurring variant of the wild-type novel coronavirus.
[0022] The novel coronavirus mentioned above is a D614G mutant strain of the novel coronavirus.
[0023] The novel coronavirus mentioned above is a wild-type novel coronavirus, a novel coronavirus Alpha strain, a novel coronavirus Beta strain, a novel coronavirus Gamma strain, a novel coronavirus Delta strain, a novel coronavirus Delta plus strain, a novel coronavirus Mu strain, or a novel coronavirus Omeprone strain.
[0024] Specifically, the novel coronavirus Omeprung strains are novel coronavirus Omeprung BA.1 strain, novel coronavirus Omeprung BA.2.12.1 strain, novel coronavirus Omeprung BA.2.75 strain, novel coronavirus Omeprung BA.3 strain, or novel coronavirus Omeprung BA.4 / 5 strain.
[0025] This invention utilizes the spike protein of the novel coronavirus as bait, screening antibody-generating memory B cells from peripheral blood mononuclear cells of infected individuals to obtain a monoclonal antibody that specifically binds to the spike protein, named P2-1D5 antibody. The P2-1D5 antibody provided by this invention has a broad-spectrum neutralizing effect against SARS-CoV-2, exhibiting strong neutralizing ability against both wild-type novel coronavirus and naturally occurring variants. This invention has significant application value for the prevention and control of the novel coronavirus and will have profound social implications. Attached Figure Description
[0026] Figure 1 The neutralizing activity of the P2-1D5 antibody against the novel coronavirus pseudovirus was measured. Detailed Implementation
[0027] The present invention will now be described in further detail with reference to specific embodiments. The given embodiments are merely illustrative of the invention and not intended to limit its scope. The embodiments provided below can serve as a guide for further improvements by those skilled in the art and do not constitute a limitation on the invention in any way.
[0028] Unless otherwise specified, the experimental methods used in the following examples are conventional methods, performed according to the techniques or conditions described in the literature in this field or according to the product instructions. Unless otherwise specified, the materials and reagents used in the following examples are commercially available. Unless otherwise specified, the quantitative experiments in the following examples are performed in triplicate, and the results are averaged. 293F cells and 293T cells are commercially available human embryonic kidney epithelial cells. The pMD18-T vector is a commercially available plasmid vector. The pcDNA3.1(+) vector: Invitrogen, catalog number V790-20.
[0029] hACE2-heLa cells (referred to in the literature as "HeLa cell lines stably expressing the ACE2 molecules") are described in the following literature: Wang, R., Zhang, Q., Ge, J., Ren, W., Zhang, R., Lan, J., Ju, B., Su, B., Yu, F., Chen, P., Liao, H., Feng, Y., Li, X., Shi, X., Zhang, Z., Zhang, F., Ding, Q., Zhang, T., Wang, X. & Zhang, L. Analysis of SARS-CoV-2 variant mutations reveals neutralization escape mechanisms and theability to use ACE2 receptors from additional species. Immunity 54, 1611-1621.e1615, doi:10.1016 / j.immuni.2021.06.003 (2021).
[0030] Example 1: Discovery and preparation of P2-1D5 antibody I. Discovery of P2-1D5 Antibody Memory B cells were isolated from peripheral blood mononuclear cells of patients recovering from SARS-CoV-2, and the antibody gene of the memory B cells was amplified to obtain the antibody sequence. Through extensive comparison, analysis, preparation, and efficacy verification, the inventors of this invention discovered a new SARS-CoV-2 IgG antibody with excellent activity, which was named P2-1D5 antibody.
[0031] The amino acid sequence of the heavy chain variable region of the P2-1D5 antibody is shown in SEQ ID NO: 1 (CDR1, CDR2, and CDR3 are located at positions 26-33, 51-58, and 97-109, respectively; CDR1, CDR2, and CDR3 are GFTFSSSV, IWYDGSNK, and ARDREITMTTFDY, respectively). The amino acid sequence of the full-length heavy chain of the P2-1D5 antibody is shown in SEQ ID NO: 2; in SEQ ID NO: 2, amino acid residues 1-19 form the signal peptide (guiding the protein to be secreted extracellularly), amino acid residues 20-139 form the heavy chain variable region, and amino acid residues 140-469 form the heavy chain constant region.
[0032] The amino acid sequence of the variable region of the light chain of the P2-1D5 antibody is shown in SEQ ID NO: 4 (CDR1, CDR2, and CDR3 are located at positions 27-32, 50-52, and 89-96, respectively; CDR1, CDR2, and CDR3 are QDISNY, DAS, and QQYDVLPL, respectively). The amino acid sequence of the full-length light chain of the P2-1D5 antibody is shown in SEQ ID NO: 5; in SEQ ID NO: 5, amino acid residues 1-19 form the signal peptide (guiding the protein to be secreted extracellularly), amino acid residues 20-125 form the variable region of the light chain, and amino acid residues 126-232 form the constant region of the light chain.
[0033] II. Preparation of P2-1D5 antibody (I) Construction of recombinant plasmids The heavy chain DNA molecule is a double-stranded DNA molecule, as shown in SEQ ID NO: 3. In SEQ ID NO: 3, nucleotides 1-891 form the promoter, nucleotides 892-2301 encode the full-length heavy chain, and nucleotides 2302-2447 form the terminator. Inserting the heavy chain DNA molecule into the pMD18-T vector yields the heavy chain expression vector.
[0034] The light chain DNA molecule is a double-stranded DNA molecule, as shown in SEQ ID NO: 6. In SEQ ID NO: 6, nucleotides 1-1037 form the promoter, nucleotides 1038-1736 encode the full-length light chain, and nucleotides 1737-1884 form the terminator. Inserting the light chain DNA molecule into the pMD18-T vector yields the light chain expression vector.
[0035] (II) Construction of recombinant cells The heavy chain expression vector and the light chain expression vector were co-transfected into 293F cells to obtain recombinant cells.
[0036] (III) Antibody Preparation 1. Take the recombinant cells obtained in step (II), culture them in DMEM medium containing 2% fetal bovine serum for 72 h, then centrifuge at 4℃ and 4000 rpm for 30 min, and collect the supernatant.
[0037] 2. Affinity chromatography Affinity chromatography column specifications: length 3cm, inner diameter 1cm; Affinity chromatography column packing material: protein A beads (Thermo, catalog number 10006D); Procedure: ① Load 300 mL of the supernatant obtained in step 1 onto an affinity chromatography column and incubate at 4 °C for 16 hours; ② Wash the column with 60 mL of binding buffer; ③ Elute the target protein with 30 mL of elution buffer and collect the post-column solution.
[0038] Binding buffer: Dissolve 112.6g of glycine and 175.2g of sodium chloride in water and bring the volume to 1L. Adjust the pH to 8.0 with sodium hydroxide.
[0039] Elution buffer: Dissolve 7.5g of glycine in water and bring the volume to 500ml. Adjust the pH to 3.0 with hydrochloric acid.
[0040] 3. Take the post-column solution obtained in step 2, concentrate it with an ultrafiltration concentrator and replace the system with PBS buffer (pH 7.2, 10mM) to obtain P2-1D5 antibody solution (antibody concentration is about 1mg / ml).
[0041] Example 2, Neutralization Test I. Preparation of Novel Coronavirus Pseudovirus Co-transfection of 293T cells with a plasmid expressing the SARS-CoV-2 Spike protein and the backbone plasmid pNL4-3R-E-luciferase yielded an infectious but non-replicating pseudovirus of SARS-CoV-2, with infectivity similar to that of live SARS-CoV-2. The backbone plasmid pNL4-3R-E-luciferase, i.e., the backbone plasmid pNL4-3R-E containing Luciferase (i.e., vector with the luciferase gene containing backbone pNL4-3R-E as described in the literature), is described in the following literature: Wang Q, Liu L, Ren W, Gettie A, Wang H, Liang Q, Shi X, Montefiori DC, Zhou T, Zhang L. Cell Rep. 2019.
[0042] The gene encoding the novel coronavirus Spike protein was inserted between the BamHII and EcoRI restriction sites of the pcDNA3.1(+) vector to obtain a plasmid expressing the novel coronavirus Spike protein. The plasmid expressing the novel coronavirus Spike protein and the backbone plasmid pNL4-3R-E-luciferase were co-transfected into 293T cells and incubated at 37°C in DMEM medium containing 10% fetal bovine serum. The cell culture supernatant was collected 60 hours after transfection; this was the viral solution containing the novel coronavirus pseudovirus. Viral solutions of pseudoviruses of 12 different novel coronavirus strains were prepared. The 12 novel coronavirus strains refer to the following: novel coronavirus D614G mutant strain, novel coronavirus Alpha strain, novel coronavirus Beta strain, novel coronavirus Gamma strain, novel coronavirus Delta strain, novel coronavirus Delta plus strain, novel coronavirus Mu strain, novel coronavirus Omeprone BA.1 strain, novel coronavirus Omeprone BA.2.12.1 strain, novel coronavirus Omeprone BA.2.75 strain, novel coronavirus Omeprone BA.3 strain, and novel coronavirus Omeprone BA.4 / 5 strain.
[0043] The Spike protein of the wild-type novel coronavirus (WT) is shown in SEQ ID NO: 7. The gene encoding the Spike protein of the wild-type novel coronavirus is described at positions 21563-25384 in the whole genome in GenBank: MN908947.3 (18-MAR-2020).
[0044] The Spike protein of the novel coronavirus D614G mutant strain has undergone the following mutation compared to the wild-type Spike protein: D614G. The coding gene for the Spike protein of the novel coronavirus D614G mutant strain is shown in SEQ ID NO: 8.
[0045] The Spike protein of the novel coronavirus Alpha strain (Pango lineage B.1.1.7) exhibits the following mutations compared to the wild-type strain: 69-70del (HV), 144del (Y), N501Y, A570D, D614G, P681H, T716I, S982A, and D1118H. The coding gene for the Spike protein of the novel coronavirus Alpha strain is described in GISAID: EPI_ISL_601443.
[0046] The Spike protein of the novel coronavirus Beta strain (Pango lineage B.1.351) exhibits the following mutations compared to the wild-type strain: L18F, D80A, D215G, 242-244del (LLA), S305T, K417N, E484K, N501Y, D614G, and A701V. The coding gene for the Spike protein of the novel coronavirus Beta strain is documented in GISAID: EPI_ISL_700450.
[0047] The Spike protein of the novel coronavirus Gamma strain (Pango lineage P.1) has the following mutations compared to the wild-type strain: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I, and V1176F. The gene encoding the Spike protein of the novel coronavirus Gamma strain is described in GISAID: EPI_ISL_792681.
[0048] The Spike protein of the SARS-CoV-2 Delta strain (Pango lineage B.1.617.2) exhibits the following mutations compared to the wild-type strain: T19R, G142D, 156-157del(EF), R158G, A222V, L452R, T478K, D614G, P681R, and D950N. The coding gene for the Spike protein of the SARS-CoV-2 Delta strain is described in GISAID:EPI_ISL_1534938.
[0049] The Spike protein of the novel coronavirus Delta plus strain (Pango lineage AY.x) has the following mutation compared to the Spike protein of the Delta strain: K417N. The coding gene of the Spike protein of the novel coronavirus Delta plus strain is described in GISAID: EPI_ISL_3019629.
[0050] The Spike protein of the novel coronavirus Mu strain (Pango lineage B.1.621) exhibits the following mutations compared to the wild-type strain: T95I, Y144T, Y145S, ins146N, R346K, E484K, N501Y, D614G, P681H, and D950N. The gene encoding the Spike protein of the novel coronavirus Mu strain is documented in GISAID: EPI_ISL_3987640.
[0051] The novel coronavirus strain Omega BA.1 (Pango lineage) The Spike protein of BA.1) underwent the following mutations relative to the Spike protein of the wild-type strain: A67V, Δ69-70 (HV), T95I, G142D, Δ143-145 (VYY), Δ211 (N), L212I, ins214EPE, G339D, S371L, S373P, S375F, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, G496S, Q498R, N501Y, Y505H, T547K, D614G, H655Y, N679K, P681H, N764K, D796Y, N856K, Q954H, N969K, L981F. The gene encoding the Spike protein of the novel coronavirus Omeprón BA.1 strain is documented in GISAID: EPI_ISL_6752027.
[0052] The Spike protein of the novel coronavirus Pango lineage BA.2.12.1 strain has the following mutations compared to the wild-type strain: T19I, 24-26del (LPP), A27S, G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452Q, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K. The gene encoding the Spike protein of the novel coronavirus strain Omeprón BA.2.12.1 is documented in GISAID:EPI_ISL_12560123.
[0053] The Spike protein of the novel coronavirus Omeprone BA.2.75 strain has undergone the following mutations compared to the wild-type strain: T19I, del24-26 (LPP), A27S, G142D, K147E, W152R, F157L, I210V, V213G, G257S, G339H, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, G446S, N460K, S477N, T478K, E484A, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K. The gene encoding the Spike protein of the novel coronavirus strain Omeprón BA.2.75 is documented in GISAID: EPI_ISL_14393635.
[0054] The Spike protein of the novel coronavirus Pango lineage BA.3 strain has undergone the following mutations compared to the wild-type strain: A67V, del69-70 (HV), T95I, G142D, del143-145 (VYY), 211del (N), L212I, G339D, S371F, S373P, S375F, D405N, K417N, N440K, G446S, S477N, T478K, E484A, Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K. The gene encoding the Spike protein of the novel coronavirus Omeprón BA.3 strain is documented in GISAID: EPI_ISL_7740765.
[0055] The Spike protein of the novel coronavirus Pango lineage BA.4 / 5 strain has the following mutations compared to the wild-type strain: T19I, 24-26del (LPP), A27S, del69-70 (HV), G142D, V213G, G339D, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, G446S, L452R, S477N, T478K, E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K. The gene encoding the Spike protein of the novel coronavirus Omeprone BA.4 / 5 strain is documented in EPI_ISL_12559461.
[0056] II. Detection of antibody neutralizing activity Test virus solutions: virus solutions of the 12 novel coronavirus strains prepared in step one.
[0057] 1. Take the P2-1D5 antibody solution prepared in Example 1 and dilute it with PBS buffer (pH 7.2, 10mM) to obtain antibody dilution solutions of various concentrations.
[0058] 2. Take a 96-well cell culture plate and add 100 μL of antibody diluent and 50 μL of test virus solution to each well (the virus concentration in the 50 μL test virus solution is 1×10⁻⁶). 4 The antibody was diluted with 50 TCID50 / ml and incubated at 37°C for 1 hour. An equal volume of PBS buffer (pH 7.2, 10 mM) was used as a virus control instead of the antibody dilution. An equal volume of DMEM medium containing 10% fetal bovine serum was used as a cell control instead of the test virus solution.
[0059] 3. After completing step 2, take the cell culture plate and inoculate each well with 100 μL of hACE2-hela cell suspension (the solvent used to prepare the cell suspension is DMEM medium containing 10% fetal bovine serum, and the concentration of hACE2-hela cells in the cell suspension is 2 × 10⁻⁶). 5 (cells / ml), incubate at 37°C for 64 hours.
[0060] 4. After completing step 3, take the cell culture plate, aspirate the supernatant, add 150 μL of lysis buffer (Microglass Biotechnology, catalog number T003, follow the instructions) to each well, and incubate at 37°C for 5 minutes.
[0061] 5. After completing step 4, take the cell culture plate and detect the luciferase activity.
[0062] Each process is configured with multiple duplicate holes.
[0063] Neutralization activity (%) = [1 - (fluorescence intensity of experimental group - fluorescence intensity of cell control) / (fluorescence intensity of virus control - fluorescence intensity of cell control)] × 100%.
[0064] Neutralization activity results are shown in Figure 1 . Figure 1 The vertical axis represents neutralizing activity (%), and the horizontal axis represents the antibody concentration (µg / ml) logarithm to base 10. The antibody concentration refers to the antibody concentration in the mixed system consisting of 100 µL of antibody dilution and 50 µL of test virus solution in step 2.
[0065] The antibody concentration at which the neutralizing activity is 50% was calculated using Prism 5 software, i.e., the IC50 value of the antibody.
[0066] Table 1 shows the IC50 values (in ng / ml) of P2-1D5 antibody against pseudoviruses of 12 novel coronavirus strains.
[0067] Table 1
[0068] The present invention has been described in detail above. For those skilled in the art, the invention can be practiced in a wide range of ways with equivalent parameters, concentrations, and conditions without departing from its spirit and scope, and without requiring unnecessary experiments. Although specific embodiments have been given, it should be understood that further modifications can be made to the invention. In summary, according to the principles of the invention, this application is intended to include any changes, uses, or improvements to the invention, including changes made using conventional techniques known in the art that depart from the scope disclosed herein. Some of the essential features can be applied within the scope of the following appended claims.
Claims
1. An IgG antibody against the spike protein of the novel coronavirus SARS-CoV-2, comprising a light chain and a heavy chain; wherein CDR1, CDR2 and CDR3 in the variable region of the heavy chain are as shown in positions 26-33, 51-58 and 97-109 of SEQ ID NO: 1, respectively; and wherein CDR1, CDR2 and CDR3 in the variable region of the light chain are as shown in positions 27-32, 50-52 and 89-96 of SEQ ID NO: 4, respectively.
2. The IgG antibody as described in claim 1, characterized in that: The heavy chain variable region is shown in SEQ ID NO: 1; The variable region of the light chain is shown in SEQ ID NO:
4.
3. The IgG antibody as described in claim 2, characterized in that: The heavy chain is either (a) or (b) as follows: (a) the protein represented by positions 20-469 of SEQ ID NO: 2; (b) the protein represented by SEQ ID NO: 2; The light chain is either (c) or (d) as follows: (c) the protein shown at positions 20-232 of SEQ ID NO: 5; (d) the protein shown in SEQ ID NO:
5.
4. A gene encoding the IgG antibody of any one of claims 1 to 3.
5. The use of the IgG antibody according to claim 1, 2 or 3 in the preparation of a medicament for inhibiting the novel coronavirus; wherein the novel coronavirus is the novel coronavirus strain Omeprone BA.2.12.1, Omeprone BA.2.75, Omeprone BA.3, Gamma, or Delta plus.
6. A drug for inhibiting the novel coronavirus, wherein the active ingredient is the IgG antibody as described in claim 1, 2 or 3; wherein the novel coronavirus is the novel coronavirus strain Omeprone BA.2.12.1, Omeprone BA.2.75, Omeprone BA.3, Gamma, or Delta plus.
7. The use of the IgG antibody according to claim 1, 2 or 3 in the preparation of a medicament for neutralizing the novel coronavirus; wherein the novel coronavirus is the novel coronavirus strain Omeprone BA.2.12.1, Omeprone BA.2.75, Omeprone BA.3, Gamma, or Delta plus.
8. A drug for neutralizing a novel coronavirus, wherein the active ingredient is the IgG antibody as described in claim 1, 2 or 3; wherein the novel coronavirus is the novel coronavirus strain Omeprone BA.2.12.1, Omeprone BA.2.75, Omeprone BA.3, Gamma, or Delta plus.
9. The use of the IgG antibody according to claim 1, 2 or 3 in the preparation of a medicament for treating COVID-19 infection; wherein the novel coronavirus is the novel coronavirus strain Omeprone BA.2.12.1, Omeprone BA.2.75, Omeprone BA.3, Gamma, or Delta plus.
10. A drug for treating COVID-19 infection, wherein the active ingredient is the IgG antibody as described in claim 1, 2 or 3; wherein the novel coronavirus is the novel coronavirus strain Omeprone BA.2.12.1, Omeprone BA.2.75, Omeprone BA.3, Gamma, or Delta plus.